The global diabetes drugs market size is expected to reach around US$ 60.2 Bn by 2026 and growing at a CAGR of around 4.3% during the forecast period 2019 to 2026.
Diabetes drugs are the medicine which are used to treat diabetes mellitus type 1 and type 2 by reducing the blood glucose level of the body. There are distinctive classes of medication concerned in the treatment of diabetes that are administered via oral route or intravenous and subcutaneous routes.
Market Dynamics
The extended revenue per capita is leading to a sedentary lifestyle, an increase in obesity and a rise in the intake of an unhealthy diet are the major reason for diabetes. The developing inclination to body inactiveness will increase diabetes occurrence and the demand for diabetes drugs, in turn, will increase. This because of the rising diabetic population, technology advancement, increase sales of novel medicines, rising aging population and growing adoption rate in developing regions are important key factors driving the rise of the diabetes drugs market. Diabetes drug markets are driven by the growing prevalence of diabetes in both developing and developed countries. In addition, the government is taking steps to control diabetes also increases the growth of the diabetes drugs market. WHO reports that 422 million people globally suffered from diabetes. WHO has also indicated that 1.5 million people died from diabetes in 2012, boosting the market boom throughout the forecast period. The growing incidence of diabetes boosts the demand in the worldwide diabetes drugs market throughout the forecast period.
By drugs, insulin segment dominated the diabetes drugs market
Based on drugs, insulin segment is dominating the global diabetes drugs market because of low-cost insulin treatment and most efficient treatment for diabetes, especially to combat type 2 diabetes. The fast growing insulin segment is, therefore, anticipated to boost the worldwide diabetes drugs market throughout the forecast period. This has also persuade private and public investments in research and development, which, in turn, will speed up market growth.
By diabetes, type 2 diabetes segment dominated the diabetes drugs market
Based on diabetes type, type 2 diabetes segment is dominating the global diabetes drugs market. The Type 2 diabetes segment accounts for vital sales of the worldwide diabetes drug market a few of the different kinds. The excessive prevalence of type 2, due to sedentary lifestyles and obesity in all age groups is attributed to this situation. Around 10% of all diabetes cases are type1, and around 90% of all cases of diabetes global are of type 2. Therefore, estimated to raise the global diabetes drugs during the forecast period.
The market research study on “Diabetes Drugs Market– Global Industry Analysis, Market Size, Opportunities and Forecast, 2019 – 2026”,offers a detailed insight into the global diabetes drugs market entailing insights on its different market segments. Market dynamics with drivers, restraints, and opportunities with their impact are provided in the report. The report provides insights into the global diabetes drugs market, its drugs, diabetes, route of administration, distribution channel, and major geographic regions. The report covers basic development policies and layouts of technology development processes. Secondly, the report covers global diabetes drugs market size and volume, and segment markets by drugs, diabetes, route of administration, distribution channel, and geography along with the information on companies operating in the market. The diabetes drugs market analysis is provided for major regional markets including North America, Europe, Asia Pacific, Latin America and Middle East and Africa. For each region, the market size and volume for different segments have been covered under the scope of the report.
In 2018, North America dominated the regional market with a maximum market share
North America held the largest market share in 2018 and is anticipated to dominate the market during the forecast period. Growing investments in research and development activities via many government institutions and a rise in the widespread presence of diabetes are a few of the factors expected to account for the good-sized diabetes drugs market share in North America. In addition, increasing knowledge about the novel anti-diabetic drugs, the introduction of anti-diabetic drugs, and beneficial reimbursement plans are probable to boost the diabetic drugs market in North America. Europe is expected to be the second most important region in terms of revenue by 2026
Asia Pacific is expected to be the biggest market for diabetes drugs and is projected to register a higher CAGR, throughout of the forecast period due to the increasing knowledge about injectable drug delivery systems, growing patient pool and shift from traditional injectable to ready-to-use injectable. China and India are prominent as the fastest growing market for diabetes drugs market because of the growing diabetic population and the growing aging population in these regions. Moreover, rising funds for diabetes curb is also boosting the increase of the diabetes tablets market in India. Brazil is expected to show lower boom rate because of patent expiry of diverse diabetes drugs.
The players profiled in the report include Bayer Pharmaceuticals, Merck, Johnson & Johnson, Sanofi, Novo Nordisk, Novartis, Takeda Pharmaceutical, AstraZeneca, Eli Lilly & Company, Boehringer Ingelheim. The companies are involved in mergers and acquisitions and new product development for expanding their market share and also for gaining competitive advantages over its competitors.
Market Segmentation
Market By Drugs Type
- Oral Anti-Diabetes Drugs
- Insulin
- Non-Insulin Injection
- Combination Drugs
Market By Diabetes Type
Market By Route of Administration
- Oral
- Subcutaneous
- Intravenous
Market By Distribution Channel
- Online Pharmacies
- Hospital Pharmacies
- Retail Pharmacies
Market By Geography
North America
Europe
- U.K.
- Germany
- France
- Spain
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Mexico
- Rest of Latin America
Middle East & Africa
- GCC
- South Africa
- Rest of Middle East & Africa
Table Of Content:
CHAPTER 1. INDUSTRY OVERVIEW
1.1. Definition and Scope
1.1.1. Definition of Diabetes Drug
1.1.2. Market Segmentation
1.1.3. List of Abbreviations
1.2. Summary
1.2.1. Market Snapshot
1.2.2. Diabetes Drugs Market By Drugs
1.2.2.1. Global Diabetes Drugs Market Revenue and Growth Rate Comparison By Drugs (2015-2026)
1.2.2.2. Global Diabetes Drugs Market Revenue Share By Drugs in 2018
1.2.2.3. Insulin
1.2.2.4. Oral Anti-Diabetes Drugs
1.2.2.5. Non- insulin Injectable
1.2.2.6. Combination Drugs
1.2.3. Diabetes Drugs Market By Diabetes
1.2.3.1. Global Diabetes Drugs Market Revenue and Growth Rate Comparison By Diabetes (2015-2026)
1.2.3.2. Global Diabetes Drugs Market Revenue Share By Diabetes in 2018
1.2.3.3. Type 1
1.2.3.4. Type 2
1.2.3.5. Type 3
1.2.4. Diabetes Drugs Market By Route Of Administration
1.2.4.1. Global Diabetes Drugs Market Revenue and Growth Rate Comparison By Route Of Administration(2015-2026)
1.2.4.2. Global Diabetes Drugs Market Revenue Share By Route Of Administration in 2018
1.2.4.3. Oral
1.2.4.4. Subcutaneous
1.2.4.5. Intravenous
1.2.5. Diabetes Drugs Market By Distribution Channel
1.2.5.1. Global Diabetes Drugs Market Revenue and Growth Rate Comparison By Distribution Channel(2015-2026)
1.2.5.2. Global Diabetes Drugs Market Revenue Share By Distribution Channel in 2018
1.2.5.3. Online pharmacies
1.2.5.4. Hospital Pharmacies
1.2.5.5. Retail Pharmacies
1.2.6. Diabetes Drugs Market By Geography
1.2.6.1. Global Diabetes Drugs Market Revenue and Growth Rate Comparison by Geography (2015-2026)
1.2.6.2. North America Diabetes Drugs Market Revenue and Growth Rate(2015-2026)
1.2.6.3. Europe Diabetes Drugs Market Revenue and Growth Rate(2015-2026)
1.2.6.4. Asia-Pacific Diabetes Drugs Market Revenue and Growth Rate(2015-2026)
1.2.6.5. Latin America Diabetes Drugs Market Revenue and Growth Rate(2015-2026)
1.2.6.6. Middle East and Africa (MEA) Diabetes Drugs Market Revenue and Growth Rate(2015-2026)
CHAPTER 2. MARKET DYNAMICS AND COMPETITION ANALYSIS
2.1. Market Drivers
2.2. Restraints and Challenges
2.3. Growth Opportunities
2.4. Porter’s Five Forces Analysis
2.4.1. Bargaining Power of Suppliers
2.4.2. Bargaining Power of Buyers
2.4.3. Threat of Substitute
2.4.4. Threat of New Entrants
2.4.5. Degree of Competition
2.5. Value Chain Analysis
2.6. Cost Structure Analysis
2.6.1. Raw Material and Suppliers
2.6.2. Manufacturing Process Analysis
2.7. Regulatory Compliance
2.8. Competitive Landscape, 2018
2.8.1. Player Positioning Analysis
2.8.2. Key Strategies Adopted By Leading Players
CHAPTER 3. MANUFACTURING DIABETES DRUG ANALYSIS
3.1. Capacity and Commercial Production Date of Global Diabetes Drug Major Manufacturers in 2018
3.2. Manufacturing Plants Distribution of Global Diabetes Drug Major Manufacturers in 2018
3.3. R&D Status and Drugs Route Of Administration of Global Diabetes Drug Major Manufacturers in 2018
3.4. Raw Materials Route Of Administrations Analysis of Global Diabetes Drug Major Manufacturers in 2018
CHAPTER 4. DIABETES DRUGS MARKET BY DRUGS
4.1. Global Diabetes Drug Revenue By Drugs
4.2. Insulin
4.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.3. Oral Anti-Diabetes Drugs
4.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.4. Non- insulin Injectable
4.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.5. Combination Drugs
4.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
CHAPTER 5. DIABETES DRUGS MARKET BY DIABETES
5.1. Global Diabetes Drug Revenue By Diabetes
5.2. Type 1
5.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.3. Type 2
5.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.4. Type 3
5.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
CHAPTER 6. DIABETES DRUGS MARKET BY ROUTE OF ADMINISTRATION
6.1. Global Diabetes Drug Revenue By Route Of Administration
6.2. Oral
6.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.3. Renewable
6.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.4. Intravenous
6.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.5. Subcutaneous
6.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
CHAPTER 7. DIABETES DRUGS MARKET BY DISTRIBUTION CHANNEL
7.1. Global Diabetes Drug Revenue By Distribution Channel
7.2. Hospital Pharmacies
7.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
7.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
7.3. Online Pharmacies
7.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
7.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
7.4. Retail Pharmacies
7.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
7.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
CHAPTER 8. NORTH AMERICA DIABETES DRUGS MARKET BY COUNTRY
8.1. North America Diabetes Drugs Market Revenue and Growth Rate, 2015 - 2026 ($Million)
8.2. North America Diabetes Drugs Market Revenue Share Comparison, 2015 & 2026 (%)
8.3. U.S.
8.3.1. U.S. Diabetes Drugs Market Revenue and Forecast By Drugs, 2015 - 2026 ($Million)
8.3.2. Market Revenue and Forecast By Diabetes, 2015 - 2026 ($Million)
8.3.3. Market Revenue and Forecast By Route Of Administration, 2015 - 2026 ($Million)
8.3.4. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
8.4. Canada
8.4.1. Market Revenue and Forecast By Drugs, 2015 - 2026 ($Million)
8.4.2. Market Revenue and Forecast By Diabetes, 2015 - 2026 ($Million)
8.4.3. Market Revenue and Forecast By Route Of Administration, 2015 - 2026 ($Million)
8.4.4. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
CHAPTER 9. EUROPE DIABETES DRUGS MARKET BY COUNTRY
9.1. Europe Diabetes Drugs Market Revenue and Growth Rate, 2015 - 2026 ($Million)
9.2. Europe Diabetes Drugs Market Revenue Share Comparison, 2015 & 2026 (%)
9.3. UK
9.3.1. Market Revenue and Forecast By Drugs, 2015 - 2026 ($Million)
9.3.2. Market Revenue and Forecast By Diabetes, 2015 - 2026 ($Million)
9.3.3. Market Revenue and Forecast By Route Of Administration, 2015 - 2026 ($Million)
9.3.4. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
9.4. Germany
9.4.1. Market Revenue and Forecast By Drugs, 2015 - 2026 ($Million)
9.4.2. Market Revenue and Forecast By Diabetes, 2015 - 2026 ($Million)
9.4.3. Market Revenue and Forecast By Route Of Administration, 2015 - 2026 ($Million)
9.4.4. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
9.5. France
9.5.1. Market Revenue and Forecast By Drugs, 2015 - 2026 ($Million)
9.5.2. Market Revenue and Forecast By Diabetes, 2015 - 2026 ($Million)
9.5.3. Market Revenue and Forecast By Route Of Administration, 2015 - 2026 ($Million)
9.5.4. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
9.6. Spain
9.6.1. Market Revenue and Forecast By Drugs, 2015 - 2026 ($Million)
9.6.2. Market Revenue and Forecast By Diabetes, 2015 - 2026 ($Million)
9.6.3. Market Revenue and Forecast By Route Of Administration, 2015 - 2026 ($Million)
9.6.4. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
9.7. Rest of Europe
9.7.1. Market Revenue and Forecast By Drugs, 2015 - 2026 ($Million)
9.7.2. Market Revenue and Forecast By Diabetes, 2015 - 2026 ($Million)
9.7.3. Market Revenue and Forecast By Route Of Administration, 2015 - 2026 ($Million)
9.7.4. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
CHAPTER 10. ASIA-PACIFIC DIABETES DRUGS MARKET BY COUNTRY
10.1. Asia-Pacific Diabetes Drugs Market Revenue and Growth Rate, 2015 - 2026 ($Million)
10.2. Asia-Pacific Diabetes Drugs Market Revenue Share Comparison, 2015 & 2026 (%)
10.3. China
10.3.1. Market Revenue and Forecast By Drugs, 2015 - 2026 ($Million)
10.3.2. Market Revenue and Forecast By Diabetes, 2015 - 2026 ($Million)
10.3.3. Market Revenue and Forecast By Route Of Administration, 2015 - 2026 ($Million)
10.3.4. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
10.4. Japan
10.4.1. Market Revenue and Forecast By Drugs, 2015 - 2026 ($Million)
10.4.2. Market Revenue and Forecast By Diabetes, 2015 - 2026 ($Million)
10.4.3. Market Revenue and Forecast By Route Of Administration, 2015 - 2026 ($Million)
10.4.4. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
10.5. India
10.5.1. Market Revenue and Forecast By Drugs, 2015 - 2026 ($Million)
10.5.2. Market Revenue and Forecast By Diabetes, 2015 - 2026 ($Million)
10.5.3. Market Revenue and Forecast By Route Of Administration, 2015 - 2026 ($Million)
10.5.4. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
10.6. Australia
10.6.1. Market Revenue and Forecast By Drugs, 2015 - 2026 ($Million)
10.6.2. Market Revenue and Forecast By Diabetes, 2015 - 2026 ($Million)
10.6.3. Market Revenue and Forecast By Route Of Administration, 2015 - 2026 ($Million)
10.6.4. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
10.7. South Korea
10.7.1. Market Revenue and Forecast By Drugs, 2015 - 2026 ($Million)
10.7.2. Market Revenue and Forecast By Diabetes, 2015 - 2026 ($Million)
10.7.3. Market Revenue and Forecast By Route Of Administration, 2015 - 2026 ($Million)
10.7.4. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
10.8. Rest of Asia-Pacific
10.8.1. Market Revenue and Forecast By Drugs, 2015 - 2026 ($Million)
10.8.2. Market Revenue and Forecast By Diabetes, 2015 - 2026 ($Million)
10.8.3. Market Revenue and Forecast By Route Of Administration, 2015 - 2026 ($Million)
10.8.4. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
CHAPTER 11. LATIN AMERICA DIABETES DRUGS MARKET BY COUNTRY
11.1. Latin America Diabetes Drugs Market Revenue and Growth Rate, 2015 - 2026 ($Million)
11.2. Latin America Diabetes Drugs Market Revenue Share Comparison, 2015 & 2026 (%)
11.3. Brazil
11.3.1. Market Revenue and Forecast By Drugs, 2015 - 2026 ($Million)
11.3.2. Market Revenue and Forecast By Diabetes, 2015 - 2026 ($Million)
11.3.3. Market Revenue and Forecast By Route Of Administration, 2015 - 2026 ($Million)
11.3.4. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
11.4. Mexico
11.4.1. Market Revenue and Forecast By Drugs, 2015 - 2026 ($Million)
11.4.2. Market Revenue and Forecast By Diabetes, 2015 - 2026 ($Million)
11.4.3. Market Revenue and Forecast By Route Of Administration, 2015 - 2026 ($Million)
11.4.4. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
11.5. Rest of Latin America
11.5.1. Market Revenue and Forecast By Drugs, 2015 - 2026 ($Million)
11.5.2. Market Revenue and Forecast By Diabetes, 2015 - 2026 ($Million)
11.5.3. Market Revenue and Forecast By Route Of Administration, 2015 - 2026 ($Million)
11.5.4. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
CHAPTER 12. MIDDLE EAST & AFRICA DIABETES DRUGS MARKET BY COUNTRY
12.1. Middle East Diabetes Drugs Market Revenue and Growth Rate, 2015 - 2026 ($Million)
12.2. Middle East Diabetes Drug Market Revenue Share Comparison, 2015 & 2026 (%)
12.3. GCC
12.3.1. Market Revenue and Forecast By Drugs, 2015 - 2026 ($Million)
12.3.2. Market Revenue and Forecast By Diabetes, 2015 - 2026 ($Million)
12.3.3. Market Revenue and Forecast By Route Of Administration, 2015 - 2026 ($Million)
12.3.4. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
12.4. South Africa
12.4.1. Market Revenue and Forecast By Drugs, 2015 - 2026 ($Million)
12.4.2. Market Revenue and Forecast By Diabetes, 2015 - 2026 ($Million)
12.4.3. Market Revenue and Forecast By Route Of Administration, 2015 - 2026 ($Million)
12.4.4. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
12.5. Rest of Middle East & Africa
12.5.1. Market Revenue and Forecast By Drugs, 2015 - 2026 ($Million)
12.5.2. Market Revenue and Forecast By Diabetes, 2015 - 2026 ($Million)
12.5.3. Market Revenue and Forecast By Route Of Administration, 2015 - 2026 ($Million)
12.5.4. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
CHAPTER 13. COMPANY PROFILE
13.1. Bayer Pharmaceuticals
13.1.1. Company Snapshot
13.1.2. Overview
13.1.3. Financial Overview
13.1.4. Drugs Portfolio
13.1.5. Key Developments
13.1.6. Strategies
13.2. Merck
13.2.1. Company Snapshot
13.2.2. Overview
13.2.3. Financial Overview
13.2.4. Drugs Portfolio
13.2.5. Key Developments
13.2.6. Strategies
13.3. Jhonson & Jhonson
13.3.1. Company Snapshot
13.3.2. Overview
13.3.3. Financial Overview
13.3.4. Drugs Portfolio
13.3.5. Key Developments
13.3.6. Strategies
13.4. Sanofi
13.4.1. Company Snapshot
13.4.2. Overview
13.4.3. Financial Overview
13.4.4. Drugs Portfolio
13.4.5. Key Developments
13.4.6. Strategies
13.5. Novo Nordisk
13.5.1. Company Snapshot
13.5.2. Overview
13.5.3. Financial Overview
13.5.4. Drugs Portfolio
13.5.5. Key Developments
13.5.6. Strategies
13.6. Novartis
13.6.1. Company Snapshot
13.6.2. Overview
13.6.3. Financial Overview
13.6.4. Drugs Portfolio
13.6.5. Key Developments
13.6.6. Strategies
13.7. Takeda Pharmaceutical
13.7.1. Company Snapshot
13.7.2. Overview
13.7.3. Financial Overview
13.7.4. Drugs Portfolio
13.7.5. Key Developments
13.7.6. Strategies
13.8. AstraZeneca
13.8.1. Company Snapshot
13.8.2. Overview
13.8.3. Financial Overview
13.8.4. Drugs Portfolio
13.8.5. Key Developments
13.8.6. Strategies
13.9. Eli Lily & Company
13.9.1. Company Snapshot
13.9.2. Overview
13.9.3. Financial Overview
13.9.4. Drugs Portfolio
13.9.5. Key Developments
13.9.6. Strategies
13.10. Boehringer Ingelheim
13.10.1. Company Snapshot
13.10.2. Overview
13.10.3. Financial Overview
13.10.4. Drugs Portfolio
13.10.5. Key Developments
13.10.6. Strategies
13.11. Others
13.11.1. Company Snapshot
13.11.2. Overview
13.11.3. Financial Overview
13.11.4. Drugs Portfolio
13.11.5. Key Developments
13.11.6. Strategies
CHAPTER 14. RESEARCH APPROACH
14.1. Research Methodology
14.1.1. Initial Data Search
14.1.2. Secondary Research
14.1.3. Primary Research
14.2. Assumptions and Scope
